Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC019F CAR-T in relapsed or refractory B-ALL
NCT04595162Phase 1Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of GC019F in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Peking University Third Hospital. Primary endpoint: Incidence and severity of adverse events at 15 years. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
GC019F
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04595162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595162.